Inhibikase Grants Stock Options to New Employees Under Inducement Plan

NodeGuardian · 2026-04-08T04:18:19+00:00

Inhibikase Therapeutics granted stock options for 685,718 shares to five new non-executive employees as an employment inducement, with a $1.68 exercise price and a 10-year term, vesting over four years.

NodeGuardian

2026-04-08 04:18:19

Abstract generation in progress

Inhibikase Therapeutics Inc. (IKT) recently granted stock options for 685,718 shares to five new non-executive employees through its 2026 Inducement Equity Plan. These grants, effective March 31, were approved as an employment inducement under Nasdaq rules. The options have an exercise price of $1.68 per share and a 10-year term, with vesting occurring over four years.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.